Yousef Amany I, El-Masry Omar S, Abdel Mohsen Mohamed A
Department of Applied Medical Chemistry, Medical Research Institute, University of Alexandria, Egypt E-mail :
Asian Pac J Cancer Prev. 2016;17(2):743-8. doi: 10.7314/apjcp.2016.17.2.743.
K-Ras activation is an early event in colorectal carcinogenesis and associated mutations have been reported in about 40% of colorectal cancer patients. These mutations have always been responsible for enhancing malignancy and silencing them is associated with attenuation of tumorigenicity. Among downstream effectors are the RAF/MEK/ERK and the PI3K/Akt signaling pathways. PI3K/Akt signaling leads to reduction of apoptosis, stimulated cell growth and enhanced proliferation. Ellagic acid (EA), a naturally occurring antioxidant, has recently emerged as a promising anti-cancer agent.
To evaluate the impact of cellular genetic make- up of two colon cancer cell lines with different genetic backgrounds, HCT-116 (K-Ras-/p53+) and Caco-2 (K-Ras+/ p53-), on response to potential anti-tumour effects of EA. In addition, the influence of K-Ras silencing in HCT- 116 cells was investigated.
Cellular proliferation, morphology and cell cycle analysis were carried out in addition to Western blotting for detecting total Akt and p-Akt (at Thr308 and Ser473) in the presence and absence of different concentrations of EA. Cell proliferation was also assessed in cells transfected with different concentrations of K-Ras siRNA or incubated with ellagic acid following transfection.
The results of the present study revealed that EA exerts anti-proliferative and dose-dependent pro-apoptotic effects. Cytostatic and cytotoxic effects were also observed. p-Akt (at Thr308 and Ser473) was downregulated. Moreover, EA treatment was found to (i) reduce K-Ras protein expression; (ii) in cells transfected with siRNA and co-treated with EA, pronounced anti-proliferative effects as well as depletion of p-Akt (at Thr308) were detected.
Cellular genetic makeup (K-Ras-/p53-) was not likely to impose limitations on targeting EA in treatment of colon cancer. EA had a multi-disciplinary pro-apoptotic anti-proliferative approach, having inhibited Akt phosphorylation, induced cell cycle arrest and showed an anti-proliferative potential in HCT-116 cells (expressing mutant K-Ras).
K-Ras激活是结直肠癌发生过程中的早期事件,约40%的结直肠癌患者存在相关突变。这些突变一直是导致恶性程度增加的原因,而使其沉默与肿瘤发生能力减弱有关。下游效应器包括RAF/MEK/ERK和PI3K/Akt信号通路。PI3K/Akt信号传导导致细胞凋亡减少、细胞生长受刺激和增殖增强。鞣花酸(EA)是一种天然存在的抗氧化剂,最近已成为一种有前景的抗癌药物。
评估具有不同遗传背景的两种结肠癌细胞系HCT-116(K-Ras-/p53+)和Caco-2(K-Ras+/p53-)的细胞遗传组成对EA潜在抗肿瘤作用反应的影响。此外,还研究了K-Ras沉默对HCT-116细胞的影响。
除了在有无不同浓度EA的情况下进行蛋白质印迹检测总Akt和p-Akt(苏氨酸308和丝氨酸473位点)外,还进行了细胞增殖、形态学和细胞周期分析。在用不同浓度的K-Ras siRNA转染的细胞中或转染后用鞣花酸孵育的细胞中也评估了细胞增殖。
本研究结果显示,EA具有抗增殖和剂量依赖性促凋亡作用。还观察到了细胞生长抑制和细胞毒性作用。p-Akt(苏氨酸308和丝氨酸473位点)表达下调。此外,发现EA处理可(i)降低K-Ras蛋白表达;(ii)在用siRNA转染并与EA共同处理的细胞中,检测到明显的抗增殖作用以及p-Akt(苏氨酸308位点)的减少。
细胞遗传组成(K-Ras-/p53-)不太可能对EA用于结肠癌治疗造成限制。EA具有多方面的促凋亡抗增殖作用,抑制了Akt磷酸化,诱导细胞周期停滞,并在HCT-116细胞(表达突变型K-Ras)中显示出抗增殖潜力。